Related Companies
|
[]
|
||||||||
Related Funds
|
[]
|
||||||||
English
|
|||||||||
oda_NewBusinessRelationAbstract|
|
|
||||||||
oda_UpdateAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
-
|
|||||||
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_AnnouncementContentSection|
|
|
||||||||
oda_NatureOfTheOtherPartyWithWhichNewBusinessRelationWillStart|
|
|
Tedarikçi (Supplier)
|
|||||||
oda_NameSurnameOrCompanyTitleOfCustomerOrSupplier|
|
|
Sanovel İlaç Sanayi ve Ticaret A.Ş.
|
|||||||
oda_IfExistsShareOfCustomerOrSupplierInNetSalesOrCostOfGoodsSoldOnLatestDisclosedProfitOrLossAndOtherComprehensiveIncomeStatementOfCompany|
|
|
-
|
|||||||
oda_IfExistsShareOfCustomerOrSupplierInTradeReceivablesOrDebtsOnLatestDisclosedStatementofFinancialPositionOfCompany|
|
|
-
|
|||||||
oda_ExpectedStartingDateOfNewBusinessRelation|
|
|
16/11/2021
|
|||||||
oda_IfExistSignificantProvisionsOfTheContractTextBlock|
|
|
-
|
|||||||
oda_ImpactOfNewBusinessRelationOnCompanyActivities|
|
|
It will have positive impact on Company's activities on a global basis.
|
|||||||
oda_ExplanationSection|
|
|
||||||||
oda_ExplanationTextBlock|
|
-Unofficial Translation- Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. ("Gen") and Sanovel İlaç Sanayi ve Ticaret A.Ş. ("Sanovel") signed a license and supply agreement ("Agreement") on 16.11.2021 that will enter into force on the date of signature. In accordance with the Agreement sale and distribution of the medicines produced by Sanovel and subjected to the Agreement will be carried out by our Company in Azerbaijan and Uzbekistan. The medicines within the scope of the Agreement are Ticagrelor used in the treatment of acute coronary diseases, Nebivalol used in the treatment of hypertension and coronary failure, and Dimetyl Fumarate used in the treatment of Multiple Sclerosis diseases. The agreement is signed for a period of 10 years at the first stage, and the contribution of this Agreement to our Company's sales is 50,500 boxes and approximately USD 950,000 (TL 9,500,000) for 2022, 86,000 boxes and approximately USD 1,350,000 (TL 13,500,000) for 2023 and 2024. 123.500 boxes and approximately USD 1.840.000 (TL 18.400.000). These numbers indicate that only contributions to the Company's sales on Azerbaijan market, numbers for Uzbekistan market will be determined in future. In addition, with this agreement, the efficiency of our Company in the Azerbaijan and Uzbekistan markets will be increased and the agreement will have a positive impact on our activities on a global basis. |
We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.